CyGenica has announced that it has raised USD $1.4 million in a seed fund investment round, led by global venture capital investor SOSV. The funding round will accelerate validation of CyGenica’s proprietary technology which enables safe, targeted, and affordable intercellular drug delivery. CyGenica’s disruptive technology addresses the problem of delivering large-molecule therapeutics into living cells without…
ImmVira Group Company, a biotechnology company focused on the development of new generation oncolytic viruses as potential cancer therapeutics, announced the signing of $10 million Series B Plus strategic financing. The round of financing will be exclusively funded by Shanghai Healthcare Capital (SHC), managed by SIIC Capital, where Shanghai Pharma is one of the founding…
Arctic Vision, a clinical-stage biotechnology company incubated by Nan Fung Life Sciences and Pivotal BioVenture Partners China in 2019, announced that it has raised $32 million Series A financing led by Morningside Ventures, together with its existing investors. Arctic Vision focuses on the development and commercialization of innovative ophthalmology therapies in China and Asia. The…